Lansoprazole is a proton pump inhibitor (PPI) which is an effective and well-tolerated treatment option in the management of acid-related disorders. Lansoprazole fast disintegrating tablet (LFDT) – a new, patient-friendly and more convenient formulation of lansoprazole which can be taken with or without water – is the first PPI to be made available as an orally disintegrating tablet. It represents an innovative drug delivery system, comprising enteric-coated microgranules of lansoprazole compressed with an inactive, rapidly dispersing matrix to form a tablet. When the tablet is placed on the tongue and sucked gently it disintegrates rapidly in the mouth, releasing the enteric-coated microgranules which are swallowed with the patient’s saliva without water. Alternatively, the tablet can be swallowed with a drink of water. Studies have shown that the bioavailability of LFDT is comparable to lansoprazole capsules, at both 15 and 30 mg doses; the indications and recommended dosages for LFDT are therefore identical to lansoprazole capsules. The new formulation may be of particular benefit to those with active life-styles who do not always have water available, patients who have difficulty in swallowing, and elderly patients.

Journal Section:
Review
Keywords:
Acid-related disorders, Lansoprazole, Orally disintegrating tablet, Patient-friendly formulation, Proton pump inhibitor
1.
Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL: The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997;24:65–70.
[PubMed]
https://doi.org/10.1097/00004836-199703000-00003
2.
Fitton A, Wiseman L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460–482.
[PubMed]
3.
Hassan-Alin M, Andersson T, Bredgerg E, Röhss K: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665–670.
[PubMed]
4.
Swan SK, Hoyumpa AM, Merritt GJ: Review article: The pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999;13(suppl 3):11–17.
5.
Howden CW: Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991;20:38–49.
6.
Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TO, Huang B, Pencyla JL: Comparing lansoprazole and omeprazole in onset of heartburn relief: Results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001;96:3089–3098.
7.
Matheson AJ, Jarvis B: Lansoprazole. An update of its place in the management of acid-related disorders. Drugs 2001;61:1801–1833.
8.
Bown RL: An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int J Clin Pract 2002;56:132–139.
9.
Nakao M, Malfertheiner P: Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998;3:21–27.
[PubMed]
https://doi.org/10.1046/j.1523-5378.1998.08024.x
10.
Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, Lai CL, Wong J: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346:2033–2038.
https://doi.org/10.1056/NEJMoa012877
11.
Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; The European Helicobacter pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection – The Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167–180.
12.
Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O’Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D: One week triple therapy for Helicobacter pylori: A multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997;41:735–739.
[PubMed]
13.
Pilotto A, Franceschi M, Leandro G, Bozzola L, Fortnato A, Rassu M, Meli S, Soffiati G, Scagnelli M, Di Mario F, Valerio G: Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol 1999;14:468–475.
14.
Patti MG, Feo CV, De Pinto M, Arcerito M, Tong J, Gantert W, Tyrrell D, Way LW: Results of laparoscopic antireflux surgery for dysphagia and gastroesophageal reflux disease. Am J Surg 1998;176:564–568.
[PubMed]
15.
Friedel D, Fisher RS: Gastrointestinal motility in the elderly. Clin Geriatr 2000;8:30–43.
16.
Tateno M, Nakamura N: Phase I study of lansoprazole (AG-1749) antiulcer agent – Capsule form. J Clin Ther Med 1991;7:51–62.
17.
Tabata T, Kashihara T, Hirai S, Kitanori N, Toguchi H: Effect of gastric pH on the absorption of a new antiulcer drug (lansoprazole) in the beagle dog. J Biopharm Sci 1991;2:319–328.
18.
Freston JW, Chiu YL, Mulford DJ, Ballard ED: Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003;17:361–367.
https://doi.org/10.1046/j.1365-2036.2003.01455.x
19.
Shimizu T, Nakano Y, Tabata T, Hamaguchi N: 19th Symposium on Particulate Preparations and Designs. October 2002, abstract A-23.
© 2003 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2003
You do not currently have access to this content.